Ashley Chan

Articles

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

September 15th 2024

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC

September 14th 2024

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

TACE Plus Lenvatinib and Pembrolizumab Improves PFS in Intermediate-Stage HCC

September 14th 2024

Lenvatinib, pembrolizumab, and TACE improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma.

Encorafenib/Binimetinib Exhibits Anti-Tumor Activity in Untreated BRAF-Mutant Advanced NSCLC

September 14th 2024

The combination of encorafenib and binimetinib showed anti-tumor responses in treatment-naïve BRAF V600E-mutant advanced non–small cell lung cancer.

T-DXd Displays Clinical Benefit in HER2-Overexpressed Metastatic NSCLC

September 11th 2024

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial

September 11th 2024

Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC

September 10th 2024

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC

September 9th 2024

The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC

September 9th 2024

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC

September 8th 2024

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

September 8th 2024

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

September 7th 2024

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

June 7th 2024

Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Decreased Azacitadine Dosing Shows Consistent Safety in Lower- and Intermediate-Risk MDS

June 3rd 2024

Treatment with a decreased dosing schedule of oral azacitidine was consistent with what has been previously known about the agent in intermediate-risk myelodysplastic syndrome.

Abiraterone Acetate/Prednisone/Apalutamide Maintains HRQOL Outcomes in Prostate Cancer

January 25th 2024

Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.

Larotrectinib Displays Efficacy, Tolerability in TRK Fusion+ Gastrointestinal Cancers

January 20th 2024

Larotrectinib led to long-lasting responses, encouraging survival, and a favorable safety profile in TRK fusion-positive gastrointestinal cancers.

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

December 12th 2023

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.